autoimmune diseases

News

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

News

Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.

News

Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.

News

Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.

News

Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road.

News

Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.